Targeted genetic correction of the phospholamban (PLN) R14del mutation restored contractile properties in human engineered cardiac tissues modeling dilated cardiomyopathy.
Absolute Event Rate: 0% vs 0%
In this study, we used three-dimensional human engineered cardiac tissue technology to directly show that phospholamban (PLN) R14del mutation impairs cardiac contractility and to demonstrate restoration of contractile properties with targeted genetic correction of this inheritable form of dilated cardiomyopathy.
Stillitano et al. (Fri,) reported a other. Targeted genetic correction of the phospholamban (PLN) R14del mutation restored contractile properties in human engineered cardiac tissues modeling dilated cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: